Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV
Advanced Science · 2026
DOI: 10.1002/advs.202510288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xun-Hong Cao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Cytomegalovirus, Herpesvirus 4, Human, Cytomegalovirus Infections, Epstein-Barr Virus Infections. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Beijing Science and Technology Plan Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Adoptive immunotherapy with third‐party virus‐specific T lymphocytes (VSTs) is effective against refractory viral infections. However, its long‐term efficacy and persistence must be enhanced. T memory stem cells (TSCMs) with superior self‐renewal and multilineage differentiation potential may enhance VSTs durability, although their antiviral capacity is underexplored. Cytomegalovirus (CMV)‐and Epstein–Barr virus (EBV)‐specific T cells are enriched with CD8⁺ TSCM through cytokine and peptide stimulation. Comprehensive preclinical evaluations show that purified TSCM‐VSTs exhibit reduced exhaustion, enhanced expansion, and stronger antiviral activity than central or effector memory VSTs (TCM or TEM). Transcriptomic and epigenetic analyses show significant enrichment of the MAPK and Wnt signaling pathways, consistent with stem‐like characteristics. In a murine model, CD8⁺ TSCM VSTs provide more effective protection against Raji‐pp65 tumors than TCM or TEM VSTs. In a phase I clinical trial, 10 patients with refractory CMV or EBV infections post‐transplant who received third‐party, off‐the‐shelf TSCM‐enriched VSTs show a 100% overall response rate and 70% complete response, with persistence up to 12 weeks and no severe adverse events. These findings support TSCM‐enriched VSTs as a potent, scalable antiviral immunotherapy and highlight TSCM proportion as a critical determinant of VSTs efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai Engineering Research Center of Stem Cells Translational Medicine, Shanghai, 200335, China.
- Institute for Regenerative Medicine, State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, 200123, China.
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Beijing Science and Technology Plan Project
- National Natural Science Foundation of China
- Beijing Outstanding Young Scientists Project
- Being Nova Program
- Technology & Innovation Project of Xiongan New area
- Beijing Natural Science Foundation
- Beijing Science and Technology Planning Project
Zitieren
APA
Cao, X. H., Pei, X. Y., Zhang, Y. Y., Xie, J., Tu, J. W., Liu, Z. J., Ding, Y. Y., Yan, C. H., Chen, Y. H., Wang, Y., Xu, L. P., Zhang, X. H., Huang, X. J., & Zhao, X. Y. (2026). Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV. Advanced Science. https://doi.org/10.1002/advs.202510288
Vancouver
Cao XH, Pei XY, Zhang YY, Xie J, Tu JW, Liu ZJ, et al. Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV. Advanced Science. 2026. doi:10.1002/advs.202510288
BibTeX
@article{Cao2026,
author = {Cao, Xun-Hong and Pei, Xu-Ying and Zhang, Yuan-Yuan and Xie, Juan and Tu, Jing-Wei and Liu, Zhuo-Jun and Ding, Yi-Yang and Yan, Chen-Hua and Chen, Yu-Hong and Wang, Yu and Xu, Lan-Ping and Zhang, Xiao-Hui and Huang, Xiao-Jun and Zhao, Xiang-Yu},
title = {Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202510288}
}
EUVIMED